Q-omics provides the consensus-scored ADAT1 profile across patient tissues and cancer cell-line models. ADAT1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ADAT1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, ADAT1 RNA expression shows 19,485 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, HNSC, and UVM as cancer lineages where ADAT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAT1 survival associations across molecular data types. ADAT1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAT1 RNA expression–survival associations across cancer types. High ADAT1 expression shows unfavorable associations in BLCA, LGG, LUSC and ACC, but favorable associations in UCS and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ADAT1 RNA expression.
This table summarizes ADAT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ADAT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAT1 shows higher tumor expression in HNSC, BLCA, KIRP, STAD, LIHC and LUAD. The HNSC box plot shows higher ADAT1 RNA expression in tumor versus normal tissue (log2 FC = +1.093, t-test p < 0.001).
This table shows molecular features associated with ADAT1 in patient tissues and cancer cell lines. In patient samples, ADAT1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
